Broadening the criteria for avoiding staging bone scans in prostate cancer: A retrospective study of patients at the Royal Marsden Hospital

BJU International

Volumn 92, Issue 7, 2003, Pages 685-689

  O'Sullivan, J M ^a,b   Norman, A R ^a   Cook, G J ^a   Fisher, C ^a   Dearnaley, D P ^a  

^a INSTITUTE OF CANCER RESEARCH   (United Kingdom)

^b INSTITUTE OF CANCER RESEARCH   (United Kingdom)

Author keywords

Bone metastases; Gleason scoring; Prostatic neoplasms; Radionuclide imaging

Indexed keywords

TUMOR ANTIGEN;

BONE SCINTISCANNING; CANCER DIAGNOSIS; CANCER GRADING; CANCER STAGING; COHORT ANALYSIS; CONFIDENCE INTERVAL; CONTROLLED STUDY; DATA ANALYSIS; DIAGNOSTIC VALUE; HISTOLOGY; HORMONAL THERAPY; HUMAN; HUMAN TISSUE; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; PROSTATE CANCER; RETROSPECTIVE STUDY; REVIEW; TUMOR BIOPSY;

AGED; BONE NEOPLASMS; COHORT STUDIES; HUMANS; MALE; NEOPLASM STAGING; PROSTATE-SPECIFIC ANTIGEN; PROSTATIC NEOPLASMS; REGRESSION ANALYSIS; RETROSPECTIVE STUDIES;

EID: 0344395155     PISSN: 14644096     EISSN: None     Source Type: Journal    
DOI: 10.1046/j.1464-410X.2003.04480.x     Document Type: Review

References (23)

1. CRUK. CRU: Cancer Statistics. In http:// www.cancerresearchuk.org 2002
2. Fleming WH, McIraith JD, King ER. Photoscanning of bone lesions utilising strontium-85. Radiology 1961; 77: 635-6
3. O'Sullivan JM, Cook GJ. A review of the efficacy of bone scanning in prostate and breast cancer. Q J Nucl Med 2002; 46: 152-9
4. BAUS. Analyses of Minimum Data Set for Urological Cancers January 1st-31st December 2001. London: The British Association of Urological Surgeons, October 2002
5. National Institute for Clinical Excellence. Improving Outcomes in Urological Cancer 2002
6. Oesterling JE, Martin SK, Bergstralh EJ, Lowe FC. The use of prostate-specific antigen in staging patients with newly diagnosed prostate cancer. JAMA 1993; 269: 57-60
7. Lee CT, Oesterling JE. Using prostate-specific antigen to eliminate the staging radionuclide bone scan. Urol Clin North Am 1997; 24: 389-94
8. Kosuda S, Yoshimura I, Aizawa T et al. Can initial prostate specific antigen determinations eliminate the need for bone scans in patients with newly diagnosed prostate carcinoma? A multicenter retrospective study in Japan. Cancer 2002; 94: 964-72
9. Gleave ME, Coupland D, Drachenberg D et al. Ability of serum prostate-specific antigen levels to predict normal bone scans in patients with newly diagnosed prostate cancer. Urology 1996; 47: 708-12
10. Rudoni M, Antonini G, Favro M et al. The clinical value of prostate-specific antigen and bone scintigraphy in the staging of patients with newly diagnosed, pathologically proven prostate cancer. Eur J Nucl Med 1995; 22: 207-11
11. Wymenga LF, Boomsma JH, Groenier K, Piers DA, Mensink HJ. Routine bone scans in patients with prostate cancer related to serum prostate-specific antigen and alkaline phosphatase. BJU Int 2001; 88: 226-30
12. Haukaas S, Roervik J, Halvorsen OJ, Foelling M. When is bone scintigraphy necessary in the assessment of newly diagnosed, untreated prostate cancer? Br J Urol 1997; 79: 770-6
13. Kemp PM, Maguire GA, Bird NJ. Which patients with prostatic carcinoma require a staging bone scan? Br J Urol 1997; 79: 611-4
14. Levran Z, Gonzalez JA, Diokno AC, Jafri SZ, Steinert BW. Are pelvic computed tomography, bone scan and pelvic lymphadenectomy necessary in the staging of prostatic cancer? Br J Urol 1995; 75: 778-81
15. Chybowski FM, Keller JJ, Bergstralh EJ, Oesterling JE. Predicting radionuclide bone scan findings in patients with newly diagnosed, untreated prostate cancer: prostate specific antigen is superior to all other clinical parameters. J Urol 1991; 145: 313-8
16. Gleason DF, Mellinger GT. Prediction of prognosis for prostatic adenocarcinoma by combined histological grading and clinical staging. J Urol 1974; 111: 58-64
17. Gleason DF. Histologic grading of prostate cancer: a perspective. Hum Pathol 1992; 23: 273-9
18. Lee N, Fawaaz R, Olsson CA et al. Which patients with newly diagnosed prostate cancer need a radionuclide bone scan? An analysis based on 631 patients. Int J Radiat Oncol Biol Phys 2000; 48: 1443-6
19. Lin K, Szabo Z, Chin BB, Civelek AC. The value of a baseline bone scan in patients with newly diagnosed prostate cancer. Clin Nucl Med 1999; 24: 579-82
20. UICC. TNM Classification of Malignant Tumours, 5th edn. New York: Wiley-Liss, 1997
21. Tumeh SS, Beadle G, Kaplan WD. Clinical significance of solitary rib lesions in patients with extraskeletal malignancy. J Nucl Med 1985; 26: 1140-3
22. Chan TY, Partin AW, Walsh PC, Epstein JI. Prognostic significance of Gleason score 3+4 versus Gleason score 4+3 tumor at radical prostatectomy. Urology 2000; 56: 823-7
23. Lau WK, Blute ML, Bostwick DG, Weaver AL, Sebo TJ, Zincke H. Prognostic factors for survival of patients with pathological Gleason score 7 prostate cancer: differences in outcome between primary Gleason grades 3 and 4. J Urol 2001; 166: 1692-7